Protective effect of procysteine on Acinetobacter pneumonia in hyperoxic conditions

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2305-2310

  Saito, Keisuke ^a,b   Kimura, Soichiro ^a   Saga, Tomoo ^a   Misonoo, Yoshi ^a   Yoshizawa, Sadako ^c   Akasaka, Yoshikiyo ^d   Ishii, Toshiharu ^a   Kuwano, Kazuyoshi ^b   Yamaguchi, Keizo ^a   Tateda, Kazuhiro ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^d TOHO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alveolar macrophages; Phagocytic activity; VAP; Ventilator associated pneumonia

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; FLUORESCEIN ISOTHIOCYANATE; INTERLEUKIN 6; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; CLINICAL STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MEGADOSE; ECTOPIC TISSUE; FEMALE; HEART INDEX; HISTOPATHOLOGY; HYPEROXIA; LOW DRUG DOSE; LUNG ALVEOLUS MACROPHAGE; LUNG HOMOGENATE; LUNG LAVAGE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; SURVIVAL RATE; VENTILATOR ASSOCIATED PNEUMONIA;

ALVEOLAR MACROPHAGES; PHAGOCYTIC ACTIVITY; VAP; VENTILATOR-ASSOCIATED PNEUMONIA;

ACINETOBACTER INFECTIONS; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIOXIDANTS; BACTERIAL LOAD; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HISTOCYTOCHEMISTRY; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; PHAGOCYTOSIS; PNEUMONIA, VENTILATOR-ASSOCIATED; PYRROLIDONECARBOXYLIC ACID; THIAZOLIDINES; TREATMENT OUTCOME;

EID: 84888786141     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt192     Document Type: Article

References (22)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
2. Efrati S, Deutsch I, Antonelli M et al. Ventilator-associated pneumonia: current status and future recommendations. J Clin Monit Comput 2010; 24: 161-8.
3. Muscedere JG, Day A, Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis 2010; 51 Suppl 1: S120-5.
4. Rello J, Ollendorf DA, Oster G et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122: 2115-21.
5. Kollef MH. What is ventilator-associated pneumonia and why is it important? Respir Care 2005; 50: 714-21.
6. Tateda K, Deng JC, Moore TA et al. Hyperoxia mediates acute lung injury and increased lethality in murine Legionella pneumonia: the role of apoptosis. J Immunol 2003; 170: 4209-16.
7. Kikuchi Y, Tateda K, Fuse ET et al. Hyperoxia exaggerates bacterial dissemination and lethality in Pseudomonas aeruginosa pneumonia. Pulm Pharmacol Ther 2009; 22: 333-9.
8. Dent LL, Marshall DR, Pratap S et al. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis 2010; 10: 196.
9. Lambert ML, Suetens C, Savey A et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011; 11: 30-8.
10. Mera RM, Miller LA, Amrine-Madsen H et al. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010; 16: 209-15.
11. Perez F, Hujer AM, Hujer KM et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471-84.
12. Lee S, Moon SO, Kim W et al. Protective role of L-2-oxothiazolidine-4-carboxylic acid in cisplatin-induced renal injury. Nephrol Dial Transplant 2006; 21: 2085-95.
13. Masterton RG, Galloway A, French G et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008; 62: 5-34.
14. Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.
15. Morrow DM, Entezari-Zaher T, Romashko J III et al. Antioxidants preserve macrophage phagocytosis of Pseudomonas aeruginosa during hyperoxia. Free Radic Biol Med 2007; 42: 1338-49.
16. Baleeiro CE, Wilcoxen SE, Morris SB et al. Sublethal hyperoxia impairs pulmonary innate immunity. J Immunol 2003; 171: 955-63.
17. Barazzone C, White CW. Mechanisms of cell injury and death in hyperoxia: role of cytokines and Bcl-2 family proteins. Am J Respir Cell Mol Biol 2000; 22: 517-9.
18. Rahman I, MacNee W. Antioxidantpharmacological therapies for COPD. Curr Opin Pharmacol 2012; 12: 256-65.
19. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994; 74: 139-62.
20. Rodrigo R, Guichard C, Charles R. Clinical pharmacologyand therapeutic use of antioxidant vitamins. Fundam Clin Pharmacol 2007; 21: 111-27.
21. Bernard GR, Wheeler AP, Arons MM et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest 1997; 112: 164-72.
22. Morris PE, Papadakos P, Russell JA et al. A double-blind placebocontrolled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome. Crit Care Med 2008; 36: 782-8.